Clinical Trial Update: A Clinical Study of Enlicitide in Participants With Severe Renal Impairment (MK-0616-032) [Phase 1]

View source ↗

Summary

A Phase 1 study of Enlicitide (MK-0616-032) in healthy participants and in individuals with severe renal impairment has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Impairment

Drugs mentioned

• Enlicitide

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Healthy, Renal Impairment | Phase 1 | Status: COMPLETED